RenovoRx CEO issues update letter to shareholders

RenovoRx provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. “Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company’s evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in RenovoRx’s mission to continue on a clinical pathway towards improving patients’ lives by using our patented products to deliver precision therapies that have the potential to transform the standard of care in difficult-to-treat cancers. With $17.2M in gross proceeds raised since the beginning of 2024, and with a proven history of prudent stewardship of our capital resources, RenovoRx has sufficient funding to advance our pivotal Phase III TIGeR-PaC clinical trial and expand the development pipeline into additional cancer indications. Our priority remains on TIGeR-PaC in Locally Advanced Pancreatic Cancer LAPC first and foremost, and its progress towards a second interim readout triggered by the 52nd event in the trial estimated late 2024, and ultimate completion thereafter. Additionally, we intend to pursue the expansion of our proprietary Trans-Arterial Micro-Perfusion TAMP therapy platform and the clinical development of our pipeline into additional cancer indications. Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies. During the first quarter, we continued to progress the TIGeR-PaC clinical trial, an ongoing randomized multi-center study in LAPC using RenovoRx’s TAMP therapy platform to evaluate its first product candidate, RenovoGem a novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care or systemic intravenous chemotherapy . …In March, important research studies were published supporting the TAMP therapy platform, including: A publication of pre-clinical studies supporting the efficacy and drug-delivery mechanism potential of TAMP to improve targeted cancer drug treatment delivery….